EndoZIP vs Apollo ESG

Clinical Trial Information

Trial Contact: Morales, Leticia, Rivera, Sophia Diane G

IRB No: W25.245.09

Principal Investigator: Teixeira, Andre F., MD

Phase: N/A

Age Group: ADULTOLDER_ADULT

ClinicalTrials.gov ID: NCT07090005

Objective

Percentage of total body weight loss at 12 months Responder rate at 12 months

Share:

Related Clinical Trials

Real-World Comparative Effectiveness of Donanemab Plus Usual Care Versus Usual Care Alone in US Patients with Early Symptomatic Alzheimer’s Disease
Intracept Minimally-invasive Procedure for Vertebrogenic back pain
A Phase III, Randomized, Open-Label, Multicenter Study of Sacituzumab Tirumotecan (sac-TMT, MK-2870) Maintenance Treatment with or without Bevacizumab versus Standard of Care in Participants with Newly Diagnosed Advanced Non-HRD Positive Ovarian Cancer Following First-Line Platinum-Based Chemotherapy (TroFuse-021/ENGOT-ov85/GOG-3102)
Are Premature Infants with Bronchopulmonary Dysplasia Requiring Tracheostomy and Ventilation at Increased Risk of Atypical Craniosynostosis?